The global personalized genomics market size is calculated at USD 12.57 billion in 2025 and is forecasted to hit around USD 52.58 billion by 2034, representing a CAGR of 17.73 from 2025 to 2034. The North America market size was estimated at USD 12.57 billion in 2024 and is expanding at a CAGR of 17.73 during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Personalized Genomics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Personalized Genomics Market, by Test Type
8.1.1. Oncology Testing
8.1.1.1. Market Revenue and Forecast
8.1.2. Infectious Disease Testing
8.1.2.1. Market Revenue and Forecast
8.1.3. Neurological Testing
8.1.3.1. Market Revenue and Forecast
8.1.4. Cardiovascular Testing
8.1.4.1. Market Revenue and Forecast
9.1. Personalized Genomics Market, by Technology
9.1.1. PCR-based Tests
9.1.1.1. Market Revenue and Forecast
9.1.2. Microarray-based Tests
9.1.2.1. Market Revenue and Forecast
9.1.3. Sequencing-based Tests
9.1.3.1. Market Revenue and Forecast
9.1.4. Others
9.1.4.1. Market Revenue and Forecast
10.1. Personalized Genomics Market, by Application
10.1.1. Diagnostics
10.1.1.1. Market Revenue and Forecast
10.1.2. Precision Medicine
10.1.2.1. Market Revenue and Forecast
10.1.3. Wellness
10.1.3.1. Market Revenue and Forecast
10.1.4. Reproductive Health
10.1.4.1. Market Revenue and Forecast
10.1.5. Sports Nutrition and Healthy Lifestyle
10.1.5.1. Market Revenue and Forecast
10.1.6. Others
10.1.6.1. Market Revenue and Forecast
11.1. Personalized Genomics Market, by End User
11.1.1. Hospitals and Clinics
11.1.1.1. Market Revenue and Forecast
11.1.2. Research Centers
11.1.2.1. Market Revenue and Forecast
11.1.3. Pharmaceutical and Biotechnology Companies
11.1.3.1. Market Revenue and Forecast
11.1.4. Diagnostic Laboratories
11.1.4.1. Market Revenue and Forecast
11.1.5. Others
11.1.5.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Test Type
12.1.2. Market Revenue and Forecast, by Technology
12.1.3. Market Revenue and Forecast, by Application
12.1.4. Market Revenue and Forecast, by End User
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Test Type
12.1.5.2. Market Revenue and Forecast, by Technology
12.1.5.3. Market Revenue and Forecast, by Application
12.1.5.4. Market Revenue and Forecast, by End User
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Test Type
12.1.6.2. Market Revenue and Forecast, by Technology
12.1.6.3. Market Revenue and Forecast, by Application
12.1.6.4. Market Revenue and Forecast, by End User
12.2. Europe
12.2.1. Market Revenue and Forecast, by Test Type
12.2.2. Market Revenue and Forecast, by Technology
12.2.3. Market Revenue and Forecast, by Application
12.2.4. Market Revenue and Forecast, by End User
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Test Type
12.2.5.2. Market Revenue and Forecast, by Technology
12.2.5.3. Market Revenue and Forecast, by Application
12.2.5.4. Market Revenue and Forecast, by End User
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Test Type
12.2.6.2. Market Revenue and Forecast, by Technology
12.2.6.3. Market Revenue and Forecast, by Application
12.2.6.4. Market Revenue and Forecast, by End User
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Test Type
12.2.7.2. Market Revenue and Forecast, by Technology
12.2.7.3. Market Revenue and Forecast, by Application
12.2.7.4. Market Revenue and Forecast, by End User
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Test Type
12.2.8.2. Market Revenue and Forecast, by Technology
12.2.8.3. Market Revenue and Forecast, by Application
12.2.8.4. Market Revenue and Forecast, by End User
12.3. APAC
12.3.1. Market Revenue and Forecast, by Test Type
12.3.2. Market Revenue and Forecast, by Technology
12.3.3. Market Revenue and Forecast, by Application
12.3.4. Market Revenue and Forecast, by End User
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Test Type
12.3.5.2. Market Revenue and Forecast, by Technology
12.3.5.3. Market Revenue and Forecast, by Application
12.3.5.4. Market Revenue and Forecast, by End User
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Test Type
12.3.6.2. Market Revenue and Forecast, by Technology
12.3.6.3. Market Revenue and Forecast, by Application
12.3.6.4. Market Revenue and Forecast, by End User
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Test Type
12.3.7.2. Market Revenue and Forecast, by Technology
12.3.7.3. Market Revenue and Forecast, by Application
12.3.7.4. Market Revenue and Forecast, by End User
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Test Type
12.3.8.2. Market Revenue and Forecast, by Technology
12.3.8.3. Market Revenue and Forecast, by Application
12.3.8.4. Market Revenue and Forecast, by End User
12.4. MEA
12.4.1. Market Revenue and Forecast, by Test Type
12.4.2. Market Revenue and Forecast, by Technology
12.4.3. Market Revenue and Forecast, by Application
12.4.4. Market Revenue and Forecast, by End User
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Test Type
12.4.5.2. Market Revenue and Forecast, by Technology
12.4.5.3. Market Revenue and Forecast, by Application
12.4.5.4. Market Revenue and Forecast, by End User
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Test Type
12.4.6.2. Market Revenue and Forecast, by Technology
12.4.6.3. Market Revenue and Forecast, by Application
12.4.6.4. Market Revenue and Forecast, by End User
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Test Type
12.4.7.2. Market Revenue and Forecast, by Technology
12.4.7.3. Market Revenue and Forecast, by Application
12.4.7.4. Market Revenue and Forecast, by End User
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Test Type
12.4.8.2. Market Revenue and Forecast, by Technology
12.4.8.3. Market Revenue and Forecast, by Application
12.4.8.4. Market Revenue and Forecast, by End User
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Test Type
12.5.2. Market Revenue and Forecast, by Technology
12.5.3. Market Revenue and Forecast, by Application
12.5.4. Market Revenue and Forecast, by End User
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Test Type
12.5.5.2. Market Revenue and Forecast, by Technology
12.5.5.3. Market Revenue and Forecast, by Application
12.5.5.4. Market Revenue and Forecast, by End User
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Test Type
12.5.6.2. Market Revenue and Forecast, by Technology
12.5.6.3. Market Revenue and Forecast, by Application
12.5.6.4. Market Revenue and Forecast, by End User
13.1. 23andMe
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Bio-Rad Laboratories
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Color Genomics
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Genetic Technology Limited
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Genomic Health
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. GNA Genotek
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Helix
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. IlluminaInc
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Interleukin Genetics
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Invite
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample